Biotech Values

[DewDiligence]

Re: Subgroups and multiple analyses

When it comes to multiple endpoints (as opposed to subgroups), PR’s tend to more honest and straightforward about the statistics. For instance, the recent PR from MYOG (#msg-10603310) said:

>>
Other secondary endpoints had clinically relevant improvements that achieved p values of less than 0.05 but were not considered statistically significant due to the pre-specified approach for multiple comparisons.
<<

In other words, these analyses had p>=0.05/k, where k is defined as in the cited article from NEJM.